stockrowLantheus Holdings, Inc.
LNTH Healthcare Drug Manufacturers Specialty & Generic
Lantheus Holdings, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 billion, up 0.50% from fiscal 2024.
- Revenue
- +1.54%
- EPS
- −16.4%
- Free cash flow
- +7.71%
- Total debt
- +0.52%
Quarter to September 2026, against a year earlier
Follow LNTH
Alert me
Lantheus Holdings, Inc. (LNTH) Altman Z-score
Lantheus Holdings, Inc.'s Altman Z-score for fiscal 2025 is 4.25, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | 4.25 | (2.42) |
| FY2024 | 6.67 | 1.35 |
| FY2023 | 5.32 | 1.94 |
| FY2022 | 3.38 | 0.35 |
| FY2021 | 3.03 | 1.52 |
| FY2020 | 1.51 | (1.26) |
| FY2019 | 2.77 | 0.68 |
| FY2018 | 2.09 | (0.04) |
| FY2017 | 2.13 | 1.27 |
| FY2016 | 0.86 | 0.76 |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.25 | — | 0.31 | |
| Retained earnings / total assets | 0.31 | — | 0.43 | |
| EBIT / total assets | 0.14 | — | 0.46 | |
| Market value of equity / total liabilities | 3.95 | — | 2.37 | |
| Sales / total assets | 0.69 | — | 0.69 | |
| Altman Z-score | Safe zone | 4.25 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 4.61 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| KNSA Kiniksa Pharmaceuticals International, plc compare | 10.4× |
| ALKS Alkermes plc compare | 5.3× |
| RDY Dr. Reddy's Laboratories Ltd compare | 5.3× |
| LNTH Lantheus Holdings, Inc. | 4.3× |
| HIMS Hims & Hers Health, Inc. compare | 4.1× |
| LQDA Liquidia Corporation compare | 4.1× |
| SUPN Indivior Pharmaceuticals Inc. compare | 3.3× |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | 1.9× |
| ELAN Elanco Animal Health Incorporated compare | 1.3× |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets
More on LNTH
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Beneish M-score
- The full statement